06.08.2012 - Belgian and UK researchers have for the first time tracked the existence of cancer stem cells in vivo. The study provides another piece of evidence that cancer stem cells are drivers of tumour recurrence.
The study published in Nature demonstrates for the first time the existence of cancer stem cells during unperturbed solid tumour growth. The team led by Cédric Blanpain from Université libre de Bruxelles found specific subsets of cells in mouse tumours that seem to be responsible for the re-growth of tumours. These findings shed new light on the controversial issue of whether cancer stem cells exist in growing tumours and may have implications for potential therapies.
Cancer stem cells are proposed to be responsible for tumour recurrence after anti-cancer treatments fail. However, evidence for cancer stem cells in solid tumours remained unproven so far. Blanpain and co-workers tracked tumour progression in mouse model of skin cancer and observe a persistent subpopulation of tumour cells with stem-like properties. There are two more groups publishing in parallel on their tracking success of cancer stem cells in Nature and Science.
29.08.2014 Just a week ago, Glaxosmithkline defused the WHO’s claim that an Ebola vaccine could be ready by 2015. Now, the British company’s own candidate vaccine is to be rushed to human trials with the help of funding from an international consortium.
24.08.2014 Germany's Morphosys is licensing a preclinical bi-specific antibody for the treatment of prostate cancer from Emergent Biosolutions. The US developer will rake in up to €138m for the commercialisation rights to the compound.
20.08.2014 Biopharmaceutical contract manufacturer Fujifilm Diosynth Biotechnologies is expanding its cell culture manufacturing capacity further with a new 2,000l single-use bioreactor at the company’s site in Billingham, UK.
08.08.2014 Boehringer Ingelheim is walking away from Swedish Orexo's prostaglandin inhibition project OX-MPI. Germany's largest researching pharmaceutical company had been responsible for the project's research and development since 2005.